LivaNova PLC (NASDAQ:LIVN) Receives $59.29 Average Target Price from Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned an average recommendation of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $59.29.

LIVN has been the subject of several recent analyst reports. Barclays decreased their price objective on shares of LivaNova from $56.00 to $55.00 and set an “equal weight” rating for the company in a research report on Thursday, May 8th. Stifel Nicolaus cut their price target on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Wolfe Research raised LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective for the company in a research report on Tuesday, May 20th. Mizuho dropped their price objective on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Finally, Robert W. Baird boosted their target price on LivaNova from $55.00 to $61.00 and gave the stock an “outperform” rating in a research note on Thursday, May 8th.

Institutional Trading of LivaNova

Hedge funds and other institutional investors have recently made changes to their positions in the company. KBC Group NV boosted its stake in shares of LivaNova by 130.5% during the fourth quarter. KBC Group NV now owns 99,928 shares of the company’s stock worth $4,628,000 after buying an additional 56,580 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of LivaNova by 29.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company’s stock valued at $292,000 after purchasing an additional 1,424 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of LivaNova by 0.5% in the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock valued at $8,240,000 after purchasing an additional 899 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of LivaNova during the fourth quarter worth approximately $2,772,000. Finally, Envestnet Asset Management Inc. raised its stake in shares of LivaNova by 15.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company’s stock worth $2,034,000 after purchasing an additional 5,850 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Trading Up 0.9%

NASDAQ LIVN opened at $43.17 on Tuesday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova has a 52 week low of $32.48 and a 52 week high of $61.94. The stock has a market capitalization of $2.35 billion, a PE ratio of 102.79 and a beta of 0.84. The firm has a 50 day moving average of $38.98 and a two-hundred day moving average of $44.41.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.